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Abstract
One of the grand challenges in the 21st century is to unravel the molecular 
elements associated to the dynamic crosstalk between immune and neuronal cells in 
neurologic diseases, and then use that knowledge to design effective neuroimmune-
mediated therapeutic strategies. In light of the critical ties between the nervous and 
immune systems, adenosine pathways may be a key element in the control of 
neuroimmune homeostasies since adenosine receptors (ARs) play an important role in
the modulation of neuronal activity and inflammatory/immune responses. Indeed, the 
omnipresence of ARs in neurons, glia and immune cells makes adenosine a key 
regulator of many facets of brain function and, therefore, a valuable target under brain 
pathological conditions. Disorders under the umbrella of neuroimmunology are not just 
the prototypic immune-mediated central (CNS) and peripheral nervous system
diseases, such as Multiple Sclerosis and Myasthenia Gravis. It is worth noting that 
virtually all of the major neurologic conditions (including Alzheimer’s disease, 
cerebrovascular disease, epilepsy, Parkinson’s, and CNS infection) are now 
recognized to have immune/inflammatory components. In the presence of inflammation 
and immune dysfunction, the adenosine system acts as a sensor, which through 
dynamic modification in the expression of ecto-enzymes and ARs, adapts neuronal 
tissue metabolism status and contributes to mechanisms deputed to neuroprotection. 
In keeping with these concepts it is becoming increasingly appreciated that drugs 
targeted on adenosine pathways can exert beneficial effects in neuroimmune 
disorders. This review aims to discuss the role of adenosine in the pathophysiology of 
neurodegenerative disorders in which the immune system plays a key role, such as
Multiple Sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease, as well as to 
highlight the mechanisms through which pharmacological modulation of the adenosine 
pathway may have potential application in their therapeutic management.
Keywords: Adenosine; Adenosine Receptors; Neurodegenerative disorders; 
Neuroimmune disorders; Adenosine-based therapies.
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Resumo
Um dos grandes desafios no século XXI é a descoberta dos elementos 
moleculares envolvidos na interação dinâmica entre as células imunológicas e 
neuronais em doenças neurológicas e aplicar esse conhecimento no desenvolvimento 
de estratégias terapêuticas eficazes com mediação neuro-imunológica. Tendo em 
conta as conexões entre os sistemas nervoso e imunológico, o sistema adenosinérgico
parece ser um elemento chave no controlo da homeostasia neuro-imunológica uma 
vez que os recetores de adenosina têm um papel importante na modulação tanto da 
atividade neuronal como das respostas inflamatórias/imunológicas. De fato, a 
omnipresença destes recetores nos neurónios, glia e em células do sistema 
imunológico faz da adenosina um regulador importante de vários aspetos da função 
cerebral e, portanto, um alvo terapêutico potencial nas patologias cerebrais. A área da 
neuroimunologia não abrange apenas as doenças de mediação imunológica 
prototípicas que afetam o sistema nervoso central e periférico, tais como a Esclerose 
Múltipla e a Miastenia Gravis. Na verdade, virtualmente todas as doenças neurológicas 
(tais como a doença cerebrovascular, infeção cerebral, doenças de Alzheimer e 
Parkinson e epilepsia) têm hoje uma componente inflamatória/imunológica 
reconhecida. Na presença de inflamação e disfunção imunológica, o sistema 
adenosinérgico atua como um sensor que através de modificações dinâmicas na 
expressão de ectoenzimas e dos seus recetores consegue adaptar o metabolismo dos 
neurónios e contribuir com efeitos neuroprotetores. Posto isto, tem vindo a crescer o 
interesse sobre os efeitos benéficos do controlo das vias da adenosina em doenças 
neuro-imunológicas. Este artigo de revisão tem objetivo de discutir o papel da 
adenosina na fisiopatologia de doenças neurodegenerativas em que o sistema 
imunológico tem um papel preponderante, tais como a Esclerose Múltipla e as 
doenças de Alzheimer, Parkinson e Huntington, assim como esclarecer os 
mecanismos pelos quais a modulação farmacológica das vias da adenosina poderá ter 
um lugar importante no seu tratamento.
Palavras-Chave: Adenosina; Receptores de Adenosina; Doenças 
Neurodegenerativas; Doenças Neuroimunes; Terapias baseadas na adenosina.
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Abbreviation List:
AD – Alzheimer’s Disease NO – Nitric Oxide
ADA – Adenosine Deaminase PD – Parkinson’s Disease
AK – Adenosine Kinase SNc – Substantia Nigra pars
AMP – Adenosine 5’-monophosphate         compacta
APP – Amyloid Precursor Protein SNr – Substantia Nigra pars
AR – Adenosine Receptor          reticulata
ATP – Adenosine 5’-triphosphate TGF-β – Transforming Growth
BDNF – Brain-derived neurotrophic factor Factor-beta
CB – Cannabinoid System TNF-α – Tumor necrosis factor alpha
CCL2 – Chemokine (C-C motif) ligand 2 Trk receptors – Tropomyosin-related
CD39 – Ecto-apyrase   kinase receptors
CD73 – Ecto-‘5-nucleotidase UPS – Ubiquitin Proteossome
CNS – Central Nervous System
COX - Ciclooxygenase
DR – Dopamine Receptor
EAE –Experimental Autoimmune Encephalomyelitis
ENT – Equilibrative nucleoside transporter
FOXP3 – Forkhead Box P3 protein
GABA – γ-Aminobutyric acid 
GLT – Glutamate transporter
Gpi – Globus Pallidus, internal segment
HD – Huntington’s Disease
IFN-γ – Interferon gamma
IL – Interleukin
iNOS – Inducible nitric oxide synthase
L-DOPA – 3,4-Dihydroxy-L-phenylalanine
MAO-B – Monoamine Oxidase B
mGlu – Metabotropic glutamate receptor
MHC – Major histocompatibility complex
MS – Multiple Sclerosis
MSN – Medium spiny neuron
NFT – Neurofibrillary Tangles
NGF – Nerve growth factor
NMDA – N-Methyl-D-aspartate
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Introduction
Adenosine has emerged as an extracellular signalling molecule able to 
coordinate homeostasis in all cells with effects on tissue protection and repair (Linden 
2005). However, in the nervous system, adenosine also exerts a rather specific
neuromodulatory role, controlling synaptic transmission and synaptic plasticity (Gomes 
2011) as well as coordinating neural networks (Sperlagh and Vizi 2011). The double 
action of this system led to the consideration of adenosine as a therapeutic target in the
management of neurologic disorders.
Part of the role of adenosine seems to be related to the regulation of 
neuroinflammatory processes and modulation of immune responses, especially in 
pathological settings, offering neuroprotection potential and a means of control of 
neurodegenerative and neuroimmune conditions (Stone et al. 2009).
The combined effects of adenosine on neuronal viability and immune responses
propelled extensive research in this field and a large body of evidence encouraging
adenosine-system-based therapies has emerged.
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Objectives
This review article aims to summarize the current evidence on the adenosine-
mediated mechanisms in the pathophysiology of neuroimmune disorders, focusing on 
neurodegenerative and autoimmune diseases and to highlight therapeutical rationale
and future potential of the adenosine system.
A short overview of the adenosine role in the nervous system function and in 
the brain immune system signaling will ensue, followed by clinical implications in 
particular neurologic disorders.
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Adenosine in the Brain
There are four known subtypes of ARs – A1, A2A, A2B and A3 ARs (Fredholm et 
al. 2011). All of them are metabotropic G-protein-coupled receptors, each of which has 
a unique pharmacological profile, tissue distribution and effector coupling (Jacobson
and Gao 2006). Traditionally, A1 and A3 ARs would negatively couple, while A2A and 
A2B ARs would positively couple to adenylate cyclase. However, since these receptors 
have shown to couple with different G proteins or different transducing systems in 
different cell types, localizations, and with varying degrees of activation, they are now 
considered pleiotropic receptors (Cunha 2005) (see Table 1).
With the observations of higher densities and more widespread distribution of 
these receptors and through the use of many available pharmacological tools and of 
receptor knockout mice strains (Wei et al. 2011 for review), the A1 and A2A ARs, have 
particularly shown impact on neuromodulation.
A1 ARs are most abundant in brain cortex, cerebellum, hippocampus and dorsal 
horn of the spinal cord but they have a widespread distribution in the brain (Ribeiro et 
al. 2003). The A2A ARs are predominantly located in the striatopallidal medium spiny γ-
aminobutyric acid (GABAergic) neurons (MSN) and olfactory bulb, but their expression 
in several other brain regions is widely recognized, though in lower levels than in the 
striatum (Sebastião and Ribeiro 2009a).
Electrophysiological and biochemical studies designed to understand the role of 
adenosine in neuronal circuits concluded that adenosine inhibits neuronal excitability 
and synaptic transmission (Dunwiddie and Massino 2001). This is achieved through 
tonic pre-synaptic inhibition of neurotransmitter release by A1 AR activation (Thompson
1992), primarily in excitatory synapses. In addition, A1 ARs also act post-synaptically, 
influencing responsiveness to excitatory stimuli by a control of N-type calcium channels 
and N-methyl-D-aspartate (NMDA) receptors (de Mendonça et al. 1995; Klishin et al.
1995) and non-synaptically, inhibiting potassium conductance and leading to neuronal
hyperpolarization (Greene and Haas 1991). On the contrary, extra-striatal pre-synaptic 
A2A ARs facilitate the release of most neurotransmitter types, including GABA (Cunha 
and Ribeiro 2000). Indeed, the observation of co-localization of A1 and A2A ARs in 
hippocampal glutamatergic nerve terminals (Rebola et al. 2005) and of functional 
interaction between the two receptor subtypes (Lopes et al. 1999) led to the proposition 
that a A1-A2A ARs heteromer provides a synaptic adenosine concentration-dependent 
switch, namely producing opposing effects on glutamate release (Ferre et al. 2007).
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Thus, A1 ARs seem to be important at lower concentrations of adenosine, 
breaking excessive synaptic activation and providing neuroprotection in physiological 
and pathological contexts while A2A ARs are stimulated with higher extracellular 
adenosine levels, particularly in stressful conditions, antagonizing the activation of A1
AR, mediating excitotoxicity and fostering synaptic plasticity mechanisms (Cunha
2005). However, other factors such as the topographical arrangement of ectoenzymes, 
transporters and receptors as well as the neuronal firing frequency may also influence 
the A1 versus A2A AR-mediated actions at each synapse where both receptors co-
localize (Sebastião and Ribeiro 2009c) (see Table 1). 
Besides these direct actions of adenosine on the neurosecretory mechanisms, 
tuning neurotransmitter release, ARs (mostly of the A2A subtype), show ability to 
oligomerize and functionally interact with other receptors, transporters, and intracellular 
second messenger systems, fine-tuning the action of several neurotransmitters and
neuromodulators for example through cannabinoid (CB)1, metabotropic glutamate 
(mGlu)5, NMDA and dopamine D2 receptors (D2R) (Ribeiro and Sebastião 2010). In 
particular, A2A ARs, can also interact with receptors for neurotrophic factors, namely 
through the transactivation of tropomyosin-related kinase (Trk)B receptors of brain-
derived neurotrophic factor (BDNF) and the facilitation of BDNF actions on synapses 
(Sebastiao et al. 2011 for review) which may have several implications for 
neurodegenerative disorders.
The sources of extracellular adenosine are either release through an 
equilibrative bi-directional nucleoside transporter (ENT) or as a result of cell damage or 
nucleotidase-mediated hydrolysis of extracellular adenine nucleotides, which have their 
own signaling properties mediated by purinergic adenosine 5’-triphosphate (ATP)
receptors (Burnstock 2012 for review). Moreover, ectonucleotidases like ecto-apyrase
(CD39) and ecto-5’-nucleotidase (CD73) are upregulated upon increased neuronal 
firing and noxious brain conditions such as hypoxia, ischemia and cell poisoning
(Fontella et al. 2004), probably in response to increases in ATP release. This elicits
large increases in the concentration of extracellular adenosine, convening a valuable
therapeutical target while governing purinergic signaling under pathological conditions
(Yegutkin 2008 for review). Adenosine itself is metabolized by adenosine kinase (AK)
and by adenosine deaminase (ADA) to adenosine 5’-monophosphate (AMP) and 
inosine, respectively. Notwithstanding, the precise location of the sites of formation and 
removal of extracellular adenosine and its sites of action need to be pinpointed to 
clarify the relation between extracellular adenosine gradients and the differential 
activation of each adenosine receptor subtype (Fredholm 2005).
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Adenosine in Neuroglia / Neuroinflammation
Research and publications in this field have generally focused on the role of 
purinergic signaling in neurons. However, the past few years brought new insights into 
our understanding of the tripartite synapse and gliotransmission in neurological 
diseases (Halassa et al. 2009). Glial cells, originally regarded as a mere structural 
support for neurons, are now known to be active and responsive to environmental 
changes, able to detect and influence neuronal function and to communicate with other 
glial and vascular cells (Fields and Burnstock 2006). The purinergic system has 
emerged as the most compelling pathway for this intercellular crosstalk and this gains 
special relevance in pathological conditions, where this interplay could be modulated 
and afford neuroprotection. Another pronounced body of evidence similarly points 
towards the influences of the adenosinergic system in the chronic neuroinflammation 
hallmark of neurodegenerative conditions.
Astrocytes have several important physiological properties related to nervous 
system homeostasis (Parpura et al. 2012 for review). The observations that ATP is a 
major gliotransmitter in vivo (Halassa and Haydon 2010) and that the well-known tonic 
A1 AR-mediated presynaptic inhibition of excitatory synaptic transmission is conveyed
by adenosine derived from an astrocytic source in vitro and in vivo (Pascual et al. 2005;
Halassa et al. 2009) demonstrate a potential of the purinergic system in the glial
modulation of neuronal function. In addition, this interaction is bidirectional, with 
astrocytes detecting and responding to neuronal firing (Fellin et al. 2006).
All four adenosine receptors are known to be present in astrocytes (Dare et al.
2007). A1Rs reduce astrocyte proliferation (Ciccarelli et al. 1994) and inhibit apoptosis 
(D’Alimonte et al. 2007) whereas occupancy of A2A and A3 ARs in primary cultures
induces reactive astrogliosis (Brambrilla et al. 2003). Paradoxically, excessive levels of 
adenosine acting on the A3 AR induces apoptosis in astrocytes (Appel et al. 2001; Di 
Iorio et al. 2002), which may be interpreted as a concentration-dependent mechanism 
to limit excessive proliferation and glial-mediated injury. Furthermore, activation of A2A
ARs in hippocampal astrocytes under physiological conditions inhibits glutamate 
uptake via glutamate (GLT)-1 transporters and stimulates astrocytic glutamate release 
(Li et al. 2001; Nishizaki et al. 2002; Matos et al. 2012), explaining the potentiation of 
glutamatergic transmission.
Besides this regulation of proliferation and survival of astrocytes, adenosine 
also has effects on their secretory functions. In fact, A1 AR activation induced nerve 
growth factor (NGF) and S100b release from astrocytes (Ciccarelli et al. 1999). A2B
POTENTIAL OF ADENOSINE-SYSTEM-BASED THERAPIES IN THE TREATMENT OF NEUROIMMUNE DISORDERS
12
ARs have shown to increase the levels of interleukin (IL)-6 (Schwaninger et al. 1997), 
while the activation of A3 ARs induced chemokine (C-C motif) ligand 2 (CCL2)
secretion (Wittendorp et al. 2004; Rosito et al. 2012) and A2A AR stimulation was 
reported to inhibit inducible nitric oxide synthase (iNOS) expression and nitric oxide 
(NO) production in astrocyte cultures (Brodie et al. 1998). Moreover, these 
neuroprotective mechanisms are particularly relevant in neuropathological conditions 
where brain injury results in a massive release of ATP and adenosine and leads to 
reactive astrogliosis with enhanced production of inflammatory cytokines, increased 
expression of major histocompatibility complex (MHC)-II and augmented production of 
free radicals (Hasko et al. 2005). Indeed, cytokines and growth factors can also interact 
with astrocyte ARs, influencing their function and expression (Abbracchio and Ceruti
2007). For instance, exposure of astrocytes to IL-6 upregulates A1 AR expression 
(Biber et al. 2001) while tumor necrosis factor alpha (TNF-α) exposure presents a
dualistic and opposite effect on A2B AR functioning after short- and long-term cytokine 
cell exposure (Trincavelli et al. 2004; Trincavelli et al. 2008). These dualistic time-
dependent effects induced by TNF-α on A2B AR-mediated action on astrogliosis are 
differently modified by inflammatory mediators in a time-dependent manner, which 
might advocate the adenosinergic system as a promising target to selectively modulate 
cerebral damage progression in the acute and chronic phases.
Microglial involvement in neurodegenerative diseases is well-established, being 
microglial activation and neuroinflammation shared features of these neuropathologies 
(Polazzi and Monti 2010 for review). Studies regarding AR subtypes expressed on 
microglial cells do not completely correlate, probably because the expression profile is 
influenced by the level of microglial activation (Dare et al. 2007). A1 ARs have shown 
antiproliferative and anti-inflammatory properties in microglia (Tsutsui et al. 2004;
Haselkorn et al. 2010) whereas activation of A2A AR stimulates proliferation (Kust et al.
1999), upregulates both cyclooxygenase (COX)-2 (Fiebich et al. 1996) and NGF 
(Heese et al. 1997) and mediates process retraction (Orr et al. 2009). Very recently, it 
was observed that adenosine augments IL-10 production by activated microglia acting 
on A2B ARs (Koscsó et al. 2012). Finally, there is scarce evidence for functional A3 ARs 
in microglial cells, namely suggesting a role in suppression of TNF-α production (Lee et 
al. 2006). The effects of adenosine will thus depend on the densities of receptor 
subtypes (which might change upon different stages of activation), their different 
affinities and signaling pathways triggered, as well as on the cellular microenvironment
(summarized in Table 1).
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There is also an important role of the adenosinergic system in the control of the 
impact of infiltrating blood cells in neuroinflammation. Of note, there is evidence on the 
anti-inflammatory potential of the A2A AR activation on macrophages (Hasko et al.
2000), monocytes (Hasko et al. 2007), dendritic cells (Panther et al. 2003) and T cells
(Csoka et al. 2008; Lappas et al. 2005), which may further explain the neuroprotective 
effects afforded by A2A ARs. 
These observations are in agreement with the theory proposed by Sitkowsky 
and Ohta (2005), that the immune system is regulated by two danger signals: an initial 
insult would first initiate a proinflammatory response and to avoid excessive collateral 
damage the tissue would issue a second danger signal which would downregulate 
inflammation. They suggested that adenosine, namely through A2A ARs, would be a 
key “OFF” signal, coordinating different stages of inflammation and redirecting immune 
responses (Sitkovsky et al. 2004). However, studies in A2A AR knockout mice, 
demonstrate that in the brain A2A AR antagonists have an anti-inflammatory effect (Yu 
et al. 2004; Yu et al. 2008; Li et al. 2009), contrasting with A2A AR effects in peripheral 
organs. Recent findings try to explain these controversies, demonstrating a critical role 
of extrasynaptic glutamate derived from brain insults in the modulation of A2A AR 
functional effects in the regulation of neuroinflammation (Dai et al. 2010).
In sum, the role of the A2A AR in neurodegeneration seems to depend upon the 
timing of the disease and the peculiar mechanisms at the basis of its etiopathology.
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Table 1: Summary of the positive and detrimental actions of the different adenosine receptor subtypes 
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 ↑ Astrocyte apoptosis
 ↑ Production of 
neuroprotective 
mediators
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Adenosine in different brain disorders
a) Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, 
and is characterized by progressive memory loss and cognitive deterioration (Blennow 
et al. 2006). 
Defining neuropathological features are: a selective synaptic failure and 
neuronal loss in several brain regions, especially the cerebral cortex and the 
hippocampus; the deposition of extracellular amyloid plaques containing the Aβ peptide 
and the formation of intraneuronal neurofibrillary tangles (NFT) (Querfurth and La Ferla
2010).
It is believed, particularly from genetic studies, that an imbalance between 
production, clearance and aggregation of Aβ peptides is crucial to AD onset (Tanzi and 
Bertram 2005). In addition, the severity of the cognitive impairment correlates with the 
levels of oligomers rather than with the total Aβ burden (Lue LF et al. 1999), proving to 
be synaptotoxic (Klyubin et al. 2008). Moreover, aggregation of Aβ oligomers into fibrils
gives rise to diffuse amyloid plaques which are associated with neuronal death, neuritic 
dystrophy, dendritic spine loss and abnormal axons (Knowles et al. 1999), leading to 
synaptic loss and disruption (Stern et al. 2004). This is an early change and structurally 
correlates with the cognitive impairment (Arendt 2005 for review).
Furthermore, there is an apparent contribution of neuroinflammatory processes 
in AD pathophysiology (Eikelenboom et al. 2006; Heneka and O’Banion 2007) and 
activated microglia and astrocytes were found to be associated with amyloid plaques 
(Wisniewski and Wiegel 1991; Stalder et al. 1999). There is also conflicting evidence 
concerning whether Aβ activates a glial inflammatory response or if glial dysfunction 
precedes amyloidogenesis (Polazzi and Monti 2010).
Adenosine, acting mainly through A1 and A2A ARs, can modulate cognition and 
memory (Sebastião and Ribeiro 2009a). There is increasing evidence suggesting 
redistribution and changes in the density of adenosine receptors in AD (Gomes et al.
2011). Autoradiography and binding studies in humans with AD have consistently 
shown a loss of A1 ARs in the hippocampus, especially in the dentate gyrus (Jansen et 
al. 1990; Kalaria et al. 1990; Ulas et al. 1993; Deckert et al. 1998). There are also 
studies demonstrating decreases in A1 ARs in the striatum (Ikeda et al. 1993), the 
temporal cortex and thalamus of AD patients (Fukumitsu et al. 2008). In contrast, the 
levels and functional activity of both A1 and A2A ARs seem to be increased in the frontal
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cortex of these patients (Albasanz et al. 2008), which is in agreement with observations
from a transgenic mouse model of AD (Arendash et al. 2006). 
Notwithstanding, an immunolocalization study revealed increased 
immunoreactivity of A1 ARs in neurons with NFT and in dystrophic neurites of senile 
plaques in the hippocampus and frontal cortex (Angulo et al. 2003). Moreover, the 
same study exposed the positive influences of the A1 AR on amyloid precursor protein 
(APP) processing and in tau phosphorylation, slowing down the progression of the 
disease (Angulo et al. 2003).
There is more limited data about the distribution of A2A ARs in AD, but
interestingly it has been found an increased expression of A2A ARs in microglial cells in 
the hippocampus and cerebral cortex (Angulo et al. 2003). As previously stated,
chronic stressful conditions elicit upregulation of A2A ARs (Rebola et al. 2005), 
encouraging the modulation of these receptors as a neuroprotective strategy. In vitro
and in vivo studies using A2A AR antagonists almost completely prevented Aβ-induced 
synaptic loss and neurotoxicity (Dall’Igna et al. 2003; Dall’Igna et al. 2007; Canas et al.
2009), raising the possibility of reversing neuronal deficits. The precise mechanism of 
this neuroprotection is still to be unveiled, but the brain anti-inflammatory properties
(Geiger et al. 2006), the protection against free radicals (Leite et al. 2011) and the 
control of glutamate excitotoxicity (Cunha 2005) derived from A2A AR blockade may all 
have an influence. Nevertheless, it is somewhat surprising the cognitive enhancement 
derived from A2A AR blockade, since A2A AR stimulation in vitro is known to facilitate 
acetylcholine secretion and enhances glutamatergic transmission in the hippocampus 
(e.g. Jin and Fredholm 1997). Indeed, currently the most used drugs in AD induce
cholinergic enhancement.
A considerable amount of information has arisen, regarding the benefits of 
adenosine receptor manipulation in AD, and this derives greatly from the impact of 
caffeine in both animal AD experimental models and epidemiological studies. Caffeine 
is a natural methylxanthine and a non-selective A1 and A2A AR antagonist (Fredholm et 
al. 1999), and neuroprotective benefits from long-term intake have been reported. 
In AD transgenic mice, long-term administration of caffeine improved cognitive 
performance, and reduced the levels of soluble Aβ fragments and of Aβ peptides
(Arendash et al. 2006). More recently, a similar study has demonstrated sustained 
reductions in plasma Aβ and decreases in both soluble and deposited Aβ in 
hippocampus and cortex (Cao et al. 2009). The same group has also shown that 
caffeine has the ability to reverse the pre-installed memory deficits and the pre-existing 
considerable Aβ burden in these models (Arendash et al. 2009). These effects are 
POTENTIAL OF ADENOSINE-SYSTEM-BASED THERAPIES IN THE TREATMENT OF NEUROIMMUNE DISORDERS
17
mimicked by selective A2A AR antagonists, strengthening the idea that A2A ARs are 
responsible for these beneficial effects. 
There is also a limited number of epidemiological studies conducted to 
determine the association between long-term (years to decades) caffeine consumption 
and the incidence of AD. Recent systematic reviews and meta-analyses from cohort 
and case-control studies have found a trend towards the protection against cognitive 
decline in AD, with highest benefit among the eldest age group (Barranco Quintana et 
al. 2007; Santos et al. 2010). However, the heterogeneous methodologies and results 
preclude definite statements in this topic.
Besides these insights on the role of adenosine in AD pathophysiology there is 
also strong evidence concerning the possible role of caffeine and ARs in other 
conditions of memory impairment. Of note, caffeine has also influence on brain 
acetylcholine, leading to concentration increases in the prefrontal cortex of rats 
(Acquas et al. 2002), an effect likely mediated by the A1 AR (Maemoto et al. 2004).
Moreover, caffeine prevents in both rodents and humans the acute memory loss 
induced by scopolamine (Riedel et al. 1995; Botton et al. 2010). This highlights the 
specific correction of the cholinergic pathway involved in caffeine memory-enhancing 
effects. However, selective A2A AR blockade did not reproduce these results 
suggesting that these receptors do not affect general processes of memory impairment 
but instead play a crucial role restricted to neurodegenerative conditions involving an 
insidious synaptic deterioration leading to memory dysfunction (Cunha et al. 2008).
There is clearly a need of more basic research on the role of the adenosinergic 
system in AD pathophysiology and associated cognitive impairment in order to 
understand its prophylactic and/or therapeutic potential.
b) Parkinson’s Disease
Parkinson’s Disease (PD) is a common neurodegenerative disorder 
characterized by a progressive loss of the dopaminergic neurons from the substantia 
nigra pars compacta (SNc) in the striatum, which leads to the typical motor symptoms 
of akinesia, bradykinesia, rigidity, resting tremor and postural abnormalities (Morelli et 
al. 2009). The etiology of the disease is still unknown but factors such as protein 
misfolding and aggregation and oxidative stress associated to mitochondrial 
dysfunction and excitotoxicity are important features in PD pathogenesis (Dauer and 
Przedborski 2003). 
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Currently, it is accepted that movement is regulated through integration of 
corticothalamic information from the striatum and output from the internal globus 
pallidus (Gpi) and substantia nigra pars reticulata (SNr) under tonic dopaminergic 
conditions (Albin et al. 1989). The GABAergic MSNs make up the major striatal output 
pathways – the monosynaptic D1R-expressing direct pathway and the striatopallidal 
D2R-expressing indirect pathway. Thus, dopamine acting through the different 
receptors in the direct and indirect pathways leads to movement facilitation and 
inhibition, respectively (Kulisevsky and Poyurovsky 2012). The important roles of 
dopamine in this control are lost in PD. Therefore, the introduction of 3,4-dihydroxy-L-
phenylalanine (L-DOPA) and of dopamine agonists was a successful strategy to 
restore the deficits in the motor loop. However this only provides a symptomatic relief, 
with no influence on disease progression and has troubling long-term consequences 
such as motor fluctuations and L-DOPA-induced dyskinesias (Stacy and Galbreath
2008; Jankovic 2005).
ARs, especially the A2A subtype, have a prominent role in several aspects of PD 
pathophysiology. A2A ARs show the ability to control D2R function through both the 
formation of heteromers and intracellular signaling pathways (Schiffmann et al. 2007)
and therefore can alter each other’s pharmacological properties such as affinity and 
desensitization in an antagonistic manner (Xie et al. 2007). The strong expression of 
A2A ARs in the striatum, namely the post-synaptic co-localization with D2R in 
GABAergic striatopallidal MSNs (Hillion et al. 2002) pinpoints a rationale for the use of 
A2A AR antagonists as an alternative or adjunctive to the dopamine-based therapies. In 
addition, A2A ARs are also expressed in GP and their blockade reduces extracellular 
GABA concentration, potentiating motor activity induced by L-DOPA (Rosin et al. 2003;
Simola et al. 2006).
There is a large number of epidemiological and experimental studies in rodent 
and primate non-human models of PD, which confirm the motor activity enhancement 
effects mediated by acute A2A AR blockade (Morelli et al. 2010; Wei et al. 2011) and 
can ameliorate symptoms even as monotherapy (Pinna et al. 2007). Moreover, 
synergistic interactions between L-DOPA and A2A AR antagonists have also been 
described suggesting that they may be co-administered to potentiate the motor
stimulant effects (Rose et al. 2006; Hodgson et al. 2010). Similar studies on the effects 
of chronic A2A AR antagonism in animal models have shown analogous findings. With 
the co-administration of A2A AR antagonists after the onset of motor fluctuations or L–
DOPA-induced dyskinesia, it was allowed a reduction in the doses of dopaminomimetic 
compounds with potentiation of motor improvements without worsening dyskinesia 
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(Armentero et al. 2011 for review). More recently, evidence from knockout studies 
pointed towards a possible contribution of A2A ARs in different brain regions and 
cellular elements other than the post-synaptic striatopallidal neurons in the attenuation 
or reversal of L-DOPA induced motor complications, a subject that requires further 
investigation (Wei et al. 2011).
Taken together, this data from non-clinical studies propelled clinical trials testing 
the use of selective A2A AR antagonists in PD patients. Indeed, five clinical trials are 
currently underway (phases I to III) to analyze the therapeutic potential of adenosine 
A2A AR (Armentero et al. 2011 for review). The most compelling evidence from these 
studies comes from the highly selective A2A AR antagonist istradefylline. Bara-Jimenez
and coworkers (2003) reported that at low doses of L-DOPA, istradefylline potentiated 
the antiparkinsonian response with less dyskinesia compared with that induced by 
optimal dose L-DOPA alone. In patients with dyskinesia, istradefylline has recently 
shown consistent and sustained increases in OFF time (Factor et al. 2010) but most 
studies in the field reported increased (although not troublesome) dyskinesias. 
However, changes in the design of the clinical trials such as dose selection, eventual 
concomitant caffeine intake and disease stage of the target population may provide 
different outcomes in the future.
In regard to the neurodegenerative process, A2A AR blockade also reduces 
dopaminergic cell loss, although the mechanism for this neuroprotective role has not 
been uncovered yet (Chen et al. 2007). The previously stated ability of the A2A AR to 
control glutamate release may be implicated, as well as the aforementioned modulation 
of glia-mediated neuroinflammation in PD. Moreover, antagonism of A2A AR also 
influences the blood-brain barrier permeability and the traffic of peripheral immune cells 
(Varani et al. 2001). Neuroprotection may also be related with the inhibition of 
monoamine oxidase B (MAO-B) reported with A2A AR antagonists (Petzer et al. 2009), 
decreasing oxidative stress and hazardous byproducts (Sagi et al. 2007). Additionally, 
there is increasing evidence that neurodegeneration begins with a synaptic 
dysfunction, which later evolves into an overt damage of neurons (Dauer and 
Przedborski 2003). Accordingly, the recent work of Gomes and colleagues has shed 
some light on the role of the A2A AR in the control of corticostriatal circuits through glial 
cell line-derived neurotrophic factor (GDNF) modulation of glutamatergic and 
dopaminergic nerve terminals (Gomes et al. 2006; Gomes et al. 2009).
Hence, A2A AR antagonism has a plethora of beneficial effects, not only 
relieving motor deficits in established PD but also showing a broader disease-modifying 
potential, arresting neurodegeneration and slowing progression. Nonetheless, concise 
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evidence on the specific mechanisms involved and their relevance is still scarce. In 
spite of the obstacles there is an exciting prospect for A2A AR antagonists as alternative 
or adjunctive therapies in PD, as further basic and clinical investigation goes on.
c) Huntington’s Disease
Huntington’s Disease (HD) is an autossomal dominant neurodegenerative 
disease characterized by progressively worsening chorea, psychiatric disturbances and 
cognitive impairment. The pathological hallmark of HD is the degeneration of striatal 
GABAergic enkephalinergic MSN’s (Mitchell et al. 1999). The molecular origin of this 
degeneration has been ascribed to a genetic mutation that leads to the production of 
an abnormal form of the protein Huntingtin (The Huntington’s Disease Collaborative 
Research Group 1993). The mechanisms of pathogenicity remain unknown but it has 
been suggested both a loss of function of the normal Huntingtin, as well as a gain of 
function related to the toxic properties of the mutated protein (Cattaneo et al. 2005).
Indeed, several lines of evidence support the idea that the mutated Huntingtin induces 
corticostriatal glutamatergic dysfunction. This includes increased glutamate release 
and decreased astrocytic glutamate clearance, together with increases in activation of 
NMDA receptors and triggering of mitochondrial dysfunction (Popolli et al. 2007).
Moreover, recent evidence demonstrated increased immune activation of macrophages 
and microglia in HD, pointing towards a role for immune dysfunction in this brain 
pathology (Björkqvist et al. 2008). 
The high density of A2A ARs in the striatum, either pre-synaptically in the 
corticostriatal afferents modulating glutamate release as well as in the post-synaptical 
MSNs, supports pathophysiological relevance of this receptor in HD (Rosin et al. 1999; 
Hettinger et al. 2001). The observation of decreased expression of A2A ARs in the 
striatum of early HD patients (Glass et al. 2000) and of transgenic mice (Blum et al.
2003) further reinforced their contribution to pathogenesis.
Several HD animal model studies (both pharmacological and genetic knockout) 
in different phases of the disease revealed changes in A2A AR expression, density 
and/or signaling. Although expression of the A2A ARs in the striatum is markedly 
decreased during HD progression (Chiang et al. 2005), striatal cells expressing the 
mutant Huntingtin have shown aberrant increases in A2A AR signaling (Varani et al.
2010; Chou et al. 2005; Tarditi et al. 2006). Despite such controversies, A2A ARs 
remain a potential target in HD.
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As previously stated, adenosine acting on A2A ARs at pre-synaptic sites, 
promotes glutamate release (Popoli et al. 2002) and is thus detrimental to neurons, 
while at post-synaptic, extra-synaptic sites and glial cells there is a speculative 
neuroprotective potential. Studies from HD animal models, regarding activation and 
blockade of A2A ARs have yielded conflicting findings in relation to neurodegeneration
since both A2A AR agonists and antagonists were capable of producing neuroprotection 
(Popoli et al. 2007 for review). A recent study in A2A AR knockout mice showed 
worsened motor performance and survival, supporting the idea that early and chronic 
blockade of A2A ARs may not be beneficial (Mievis et al. 2011). This might reflect the 
pre- versus post-synaptic effects of A2A ARs, and is in line with the unexpected ability of 
A2A AR antagonists to potentiate NMDA-mediated toxicity (Popoli et al. 2007). The 
same controversy exists in regard to mitochondrial and metabolic dysfunction with 
findings of either protection or increase of striatal MSN lesion (Alfinito et al. 2003; Fink 
et al. 2004).
Moreover, it has been shown that A2A AR agonists can enhance ubiquitin 
proteossome system (UPS) activity (Chiang et al. 2009), which may be of value since 
Huntingtin aggregate formation and UPS dysfunction are major features of HD (Wang 
et al. 2008).
In addition, normal Huntingtin has beneficial antiapoptotic actions and 
contributes to the production and delivery of BDNF, namely to striatal targets, and this 
supply is decreased in HD (Zuccato and Cattaneo 2007). BDNF is particularly 
important for the survival and plasticity phenomena of corticostriatal synapses
(Cattaneo et al. 2005) and A2A AR agonists are able to transactivate the TrkB BDNF 
receptor and regulate BDNF levels (Sebastião and Ribeiro 2009b). Indeed, A2A ARs
have shown a crucial role in this regulation (Tebano et al. 2010), which provides 
another neuroprotective mechanism afforded by adenosine. However, BDNF can also
contribute to cell death, depending on the receptor activated (Gomes et al. 2011), 
which further complicates this controversy.
Finally, A2A AR antagonism is generally accepted as a neuroprotective strategy, 
through the control of the neuroinflammatory component of neurodegenerative 
diseases, including HD. Furthermore, A2A ARs expressed in bone marrow-derived 
inflammatory cells have proved to be important contributors to striatal damage in 
transgenic models of HD (Huang et al. 2006).
It appears that the disease stage and time-frame, the drug administration 
protocol, and the clinical manifestations might play critical roles in evaluating the future 
therapeutic potential of A2A AR ligands (Popoli et al. 2008). HD is thus a special case 
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where the complexity of the disease combines with the complexity of A2A AR 
pharmacology, possibly yielding biphasic neurotoxic-neuroprotective effects and
making it difficult to establish if this is a target of interest.
d) Multiple Sclerosis
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the CNS, 
classically defined as an auto-reactive T-cell-driven damage directed towards
oligodendrocytes and the myelin sheath surrounding central axons, with features of 
mononuclear cell infiltration and inflammatory damage (Prat and Antel 2005). However, 
more recent work has indicated prominent and widespread neuronal damage early in 
the disease (Vogt et al. 2009). This led to the hypothesis of MS as an inflammatory 
demyelinating and neurodegenerative disease but it remains elusive if there is a 
sequence of events or distinct pathological processes culminating in disease (Herz et 
al. 2010). Research focus has thus shifted towards the involvement of cellular and 
molecular mechanisms in this neuroimmune crosstalk. In addition, astrocytes and 
microglia have shown a dual role in MS, both promoting damage and inflammation as 
well as restoring the damaged tissues (Williams et al. 2007; Muzio et al. 2007).
Besides the roles in neuro-glial and glia-glial communication, not much is known 
regarding purinergic signaling in MS. Adenosine levels are decreased in the blood of 
MS patients, together with an increase of TNF-α (Mayne et al. 1999). In addition, blood 
immune cells and glial cels from MS patients show decreased expression of the A1 AR, 
suggesting a dysfunction of this receptor in the pathogenesis of the disease (Johnston 
et al. 2001). Consistently, studies using experimental autoimmune encephalomyelitis 
(EAE), the most widely used animal model of MS, found that A1 AR stimulation protects 
against neuroinflammation, demyelination and oligodendrocyte cytotoxicity (Tsutsui et 
al. 2004). This is further supported by the recent finding that suppression of EAE-
induced neuroinflammation and neurobehavioral deficits by glucocorticoid treatment is 
accompanied by a concurrent increase in A1 AR expression in monocytoid cells 
(Tsutsui et al. 2008). Moreover, adenosine directly promotes oligodendrocyte 
progenitor cell differentiation and myelination (Stevens et al. 2002) and stimulates their 
migration via A1 ARs (Othman et al. 2003).
More recently, chronic intake of caffeine has shown the surprising ability to 
upregulate A1 ARs, transforming growth factor-beta (TGF-β) and to suppress interferon-
gamma (IFN-γ) in EAE guinea pigs (Chen et al. 2010). This data supports the view of 
A1 AR-mediated shift from Th1 to Th2 cell function in the attenuation of pathology 
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(Chen et al. 2010) and provides a neurobiological basis for epidemiological 
investigation into the possible relationship between caffeine consumption and 
development of multiple sclerosis in humans.
Furthermore, pharmacological blockade of A2A AR protected mice from EAE 
induction, highlighting the critical role of adenosine in the modulation of EAE, although 
the exact mechanisms remain to be clarified (Mills et al. 2008).
In the murine EAE model of MS, adenosine can also exacerbate 
immunopathological mechanisms. Infiltrating lymphocytes into the CNS requires the 
expression of CD73 either on T cells or in the CNS for disease induction (Mills et al.
2008). This means that the anti-inflammatory effects of adenosine can be offset by the 
effect on the access of pathogenic T-cells to the CNS.
Moreover, it was demonstrated that CD39 is expressed in a subset of forkhead 
box P3 (FOXP3)-expressing regulatory T cells, the numbers of which are strikingly 
reduced in patients with relapsing-remitting MS (Borsellino et al. 2007). These cells are 
suggested to play a role in the suppression of autoimmune damage, and their reduction 
in MS might impair the control of IL-17-mediated inflammation (Fletcher et al. 2009). In 
addition, lymphocytes from MS patients have shown an increased CD39 activity, which 
may provide a protective mechanism by fostering AR-mediated anti-inflammatory
actions (Spanevello et al. 2010).
Besides CD73 and CD39, also ADA is involved in lymphocyte functioning in 
MS. ADA is known to control growth, proliferation, differentiation and migration of 
lymphocytes (Pérez-Aguilar et al. 2010). Since lymphocytes from MS patients exhibit 
reduced ADA activity (Vivekanandhan et al. 2005), this may further contribute to their 
infiltration in the CNS.
There is mounting evidence on the link between adenosine and the etiology of 
MS. The multifaceted role of this molecule and the myriad of integrative mechanisms in 
the control of immune responses open new avenues for treatments to be pursued in 
the future, as additional understanding is provided.
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Discussion
The future prospects for adenosine-system-based therapies in chronic 
neurodegenerative diseases seem promising. However, in spite of the vast 
contributions of ARs to neuroprotection mechanisms and to the regulation of 
inflammation in the last few years, there are still several open questions which deserve 
special attention.
Adenosine elicits a multitude of effects in different cells, and factors such as
expression, density, localization, transducing systems, and functions of ARs 
(particularly the A2A) are subject to modifications upon brain activity or pathology. The 
same promiscuity occurs with the institution of pharmacological modulation of ARs or 
adenosine metabolism pathways and with caffeine intake, especially in a long-term 
basis. Moreover, the sources and pathways of generation of extracellular adenosine 
are still not fully uncovered in order to understand the dynamics of these receptors.
In regard to the experimental models of neurodegeneration, it is difficult to draw 
conclusions on the precise role of ARs in chronic conditions, since evidence derives in 
great part from acute injury models and some do not take into account the age of the 
animal. This is particularly relevant since conditions like AD and PD are strikingly
prevalent in the elderly. Furthermore it is uncertain the translational potential of such 
studies into the human brain.
It seems well established that A1 AR activation affords neuroprotection while 
blockade of A2A ARs attenuates the burden of most brain disorders. As previously 
proposed, this would mean that a combination of AK inhibitors and antagonists of A2A
ARs would achieve the most neuroprotective potential (Cunha 2005). However this 
impact can only be predicted if more light is shed on when and how extracellular 
adenosine levels change in the brain (including synapse, neuro-glial domain, glia-glial 
domain or gliovascular domain), the blood-brain barrier and in infiltrating myeloid cells.
In addition, these fluctuations may vary with disease stage and between diseases,
further complicating the scenario.
The recognition of the dual role of neuroinflammation on neurodegeneration and 
neuroprotection and the importance of the adenosinergic system in the control of the 
balance between tissue injury and repair also turned attention towards ARs as 
modulators of glial and immune functions. The apparent primordial physiological 
protective function of adenosine following acute insults may be overshadowed by its 
reduced ability to protect against more chronic injury. Adenosine signals are 
endogenously protective, but imperfect and inconsistent. For instance, blocking the A2A
POTENTIAL OF ADENOSINE-SYSTEM-BASED THERAPIES IN THE TREATMENT OF NEUROIMMUNE DISORDERS
25
AR in the brain to suppress inflammation may exacerbate peripheral proinflammatory 
effects. Moreover, interactions between activation of astrocytes and microglia are likely 
of great importance in this modulation since each of the glial cells expresses ARs and
has the opposite effects of enhancement of immune responses and limiting of CNS 
inflammation. It is thus fundamental the understanding of gliotransmission and of the 
mechanisms encompassing other glial interplays in the progression and outcome of 
neurological diseases (Verkhratsky et al 2012 for review).
In regard to the specific neurodegenerative disorders, there are other particular 
caveats worth mentioning. In AD it is still difficult to disentangle the impacts of A2A AR 
blockade on cognitive impairment from those related to disease pathophysiology itself.
A putative target to be tested is related to cholinergic function. There is a deficiency in 
cholinergic projections in AD and presynaptic α-7 nicotinic acetylcholine receptors are 
essential for cognitive processing. Since the levels of such receptors are increased in 
early AD (Ikonomovic et al. 2009) and the activation of A2A ARs exerted control of α-7 
nicotinic currents in models of hippocampus (Fernandes et al. 2008), it can be 
proposed another mechanism of regulation of plasticity phenomena through A2A AR 
inhibition.
The last years of research revolutionized the classic view of PD. Indeed, 
neurodegeneration extends into locations other than the striatum and also occurs in 
different nerve terminals. In addition, the basal ganglia pathways of motor control are 
far more intricate than previously thought, with plenty of interactions and feedback 
loops. Moreover, the complete characterization and the development of ligands 
targeting A2A AR-containing heteromers must be considered in the future. These show 
unique pharmacological properties and are more selective in localization than each of 
the constituent receptors, while allowing us to better comprehend the disease 
pathophysiology (Ciruela et al. 2011 for review). Of note, the observation of 
heteromeric complexes and synergistic effects of A2A and mGlu5 receptors in the 
striatum (Ferré et al. 2002; Kachroo et al. 2005) underline the potentialities of the 
simultaneous blockade of these receptors in PD treatment.
The discrepancies in the effects of A2A ARs in HD have been the major issue in 
the development of new therapies. A2A AR agonists seem to be mostly beneficial in late 
stages of degeneration while the protective effects of A2A AR blockade depend on the 
strength of post-synaptic inhibition. Huntingtin alters the function and the expression of 
A2A ARs, which further challenges this hypothesis. Here too, the formation of A2A AR-
containing heteromers provides a more specific and useful target. Very recently, a 
study with T1-11, a dual-action drug with weak A2A AR agonist potential that inhibits 
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ENT-1, hindering adenosine uptake, substantially delayed HD progression (Huang et 
al. 2011). This dual function provides a new therapeutic concept that may be applicable 
to other neurotransmitter systems and facilitate the development of new drugs for 
neurodegenerative diseases.
The investigation of the specific role of the adenosinergic system in MS 
pathophysiology is still in its infancy. Most studies have rather focused on ATP
receptors. However, MS can be seen as a model of protective autoimmunity, in which 
the brain natural repair mechanisms are impaired (Martino 2004). A1 ARs seem to be 
important in the restoration of such mechanisms and induction of increases in 
extracellular adenosine seems a reliable strategy, namely through the enhancement of 
ectonucleotidases function.
Neurotrophic factors have pleiotropic effects in the brain beyond the neuronal 
trophic support and there is a lack of studies on the BDNF-mediated neuroprotection in 
pathological conditions. The same applies to the excitotoxicity mechanisms involved in 
neurodegenerative disorders (Dong et al. 2009).
The open questions may be answered with the exploration of the potentialities 
of the more recently revealed A2B and A3 ARs. Likewise, the development of more 
agonists and antagonists of ARs, allosteric enhancers or AR-containing heteromers,
with different affinities and properties tries to bring some insight, namely targeting an 
adequate balance of pre- versus post-synaptic action and minimizing side effects.
In addition, the action of ectonucleotidases in the governation of purinergic 
signaling in ATP versus adenosine receptors deserves special attention ever since the 
existence of oligomeric complexes between them was demonstrated (Schicker et al.
2009). This adds to the network of overlapping biological reactions and the crosstalk of 
signaling pathways achieved in membrane microdomains (Lasley 2011 for review). It is 
hence noteworthy to mention the bolstering of ectonucleotidase function as a 
therapeutic alternative.
The intracellular metabolic pathways of adenosine are also subject of research 
as targets of adenosine augmentation therapies: inosine promotes axonal growth in the 
CNS and acts on ARs, yielding significant but not totally clear preclinical evidence in 
the treatment of neuroinflammatory disorders; xanthine oxidase inhibitors reduce free 
radical production and ultimately lead to increases in adenosine; urate has gained 
recognition because of its antioxidant effects and neuroprotective potential in MS 
models. Moreover, recent epidemiological and clinical studies show an inverse 
relationship between urate exposure and PD, serving as an independent prognostic 
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biomarker (Morelli et al. 2010). However such an approach is of little value in 
influencing disease pathophysiology, but rather providing symptomatic relief. 
It was also observed that pathologically increased expression of AK is linked to 
astrogliosis in many CNS pathologies, leading to reductions in adenosine tone and
leaving neurons more susceptible to damage (Boison 2008). Thus, it is logical the
proposition of AK inhibitors in the treatment of such disorders. Instead, the significant 
side effects of the systemic use of these drugs pushed forward a new era of focal 
approaches of augmentation of nucleoside function, as already tried for epilepsy. This 
includes intelligent and ideally suited management strategies such as polimer-based 
adenosine delivery, stem cell-based adenosine delivery and gene therapy.
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Conclusions
In this regard, there is an entire spectrum of (patho)physiological mechanisms 
and facets that are subject to adenosinergic regulation. Therapies based on this 
approach will depend on the timing of treatment, with respect to the therapeutic 
window, the stage and progression of damage and the duration and monitoring for both 
beneficial and adverse events. This precise time-space coincidence will only be 
achieved through more awareness on how adenosine signals are perceived, 
discriminated, sustained and terminated.
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Annex A
“Potencial das terapias baseadas no sistema da adenosina no 
tratamento de doenças Neurodegenerativas” – Resumo
Introdução
A adenosina é reconhecida como uma molécula de sinalização extracelular 
capaz de coordenar a homeostasia em todas as células, com efeitos na proteção e 
reparação tecidular. No entanto, no sistema nervoso central, esta molécula também 
exerce ações neuromodulatórias específicas no controlo da transmissão e plasticidade 
sinápticas e na coordenação de circuitos neuronais. Esta atividade dupla do sistema 
adenosinérgico levou à consideração da adenosina como um alvo terapêutico no 
tratamento de doenças neurológicas. Parte deste papel da adenosina parece estar 
relacionado com a regulação de processos neuroinflamatórios e modulação das 
respostas imunológicas, particularmente em circunstancias patológicas, conferindo um 
potencial neuroprotetor e uma oportunidade de controlo de doenças 
neurodegenerativas e neuroimunes.
Os efeitos combinados da adenosina na viabilidade neuronal e na inflamação 
suscitaram o interesse de vários grupos nesta área de investigação, e existem 
evidências emergentes que encorajam terapias baseadas neste sistema.
Objetivos
Este artigo de revisão bibliográfica tem o objetivo de sumarizar as evidências 
atuais no que diz respeito aos mecanismos mediados pela adenosina na fisiopatologia 
de distúrbios neuroimunes (focando doenças neurodegenerativas e autoimunes), 
assim como salientar as oportunidades terapêuticas e o potencial futuro do sistema 
adenosinérgico.
A Adenosina no Sistema Nervoso Central
São conhecidos quatro subtipos de recetores de adenosina – A1, A2A, A2B e A3. 
Todos eles são recetores metabotrópicos acoplados à proteína G, mas cada um tem 
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um perfil farmacológico, uma distribuição tecidular e vias de sinalização 
característicos. Ao nível cerebral, os recetores A1 e A2A demonstram um impacto 
particular na neuromodulação. Os recetores A1 são mais abundantes no córtex 
cerebral, cerebelo, hipocampo e corno posterior da espinal medula, enquanto que os 
recetores A2A predominam nos neurónios médios espinhosos do estriado. No entanto, 
ambos os recetores têm uma distribuição alargada no sistema nervoso central, embora 
com níveis de expressão mais baixos. 
Estudos eletrofisiológicos e bioquímicos sobre o papel da adenosina nos 
circuitos neuronais concluíram que esta molécula é capaz de inibir a excitabilidade dos 
neurónios e a transmissão sináptica. Isto é conseguido através de inibição pré-
sináptica tónica da libertação de neurotransmissores causada pela ativação dos 
recetores A1, em específico nas sinapses excitatórias. Além disso, também existem 
contribuíções pós- e extra-sinápticas da ativação A1, que controlam a resposta a 
estímulos excitatórios. Por outro lado, a ativação pré-sináptica de recetores A2A facilita 
a libertação de vários neurotransmissores. Com efeito, a observação de co-localização 
e interação funcional entre estes dois subtipos de recetor no hipocampo levou à 
proposição de que um heterómero composto pelos recetores A1 e A2A funcionaria 
como um interruptor sináptico dependente da concentração de adenosina, produzindo 
nomeadamente efeitos opostos na libertação de glutamato. Desta forma, os recetores 
A1 parecem ter importância neuroprotetora perante concentrações baixas de 
adenosina, evitando ativação sináptica excessiva, enquanto que os recetores A2A são 
estimulados com concentrações mais elevadas, particularmente em condições de 
stress e antagonizando a ativação A1, promovendo excitotoxicidade e sustentando 
fenómenos de plasticidade neuronal.
Para além dos efeitos nos mecanismos neuro-secretores, os recetores de 
adenosina têm ainda a capacidade de interagir funcionalmente com outros recetores, 
transportadores, e sistemas de sinalização intracelular, ajustando e adaptando a ação 
de vários neurotransmissores, neuromoduladores e fatores neurotróficos.
Os aumentos de adenosina extracelular resultam da libertação por um 
transportador equilibrativo, de dano celular ou da hidrólise de nucleotidos de adenina 
extracelulares por nucleotidases. As ectonucleotidases são estimuladas mediante 
condições nóxicas, provavelmente em resposta a um aumento de ATP extracelular, 
gerando níveis elevados de adenosina que constituem uma oportunidade terapêutica 
ao governar a sinalização purinérgica em circunstâncias patológicas. A adenosina é 
metabolizada a nível intracelular pela adenosina cinase e pela adenosina deaminase, 
vias que também são objeto de investigação.
POTENTIAL OF ADENOSINE-SYSTEM-BASED THERAPIES IN THE TREATMENT OF NEUROIMMUNE DISORDERS
44
A Adenosina na Neuroglia / Neuroinflamação
As células gliais, originalmente encaradas como um mero suporte estrutural 
dos neurónios, têm a capacidade de adaptação e de resposta a estímulos ambientais, 
nomeadamente detetando e influenciando a função neuronal e comunicando com 
outras células gliais e vasculares. O sistema adenosinérgico ganhou popularidade 
como mediador desta comunicação intercelular, com especial relevância em 
circunstâncias patológicas onde esta interação pode ser modulada e gerar 
neuroprotecção.
Os astrócitos apresentam uma interação bidirecional com os neurónios que é 
parcialmente mediada pela adenosina. Os recetores de adenosina dos astrócitos são 
responsáveis pela regulação da sua proliferação, sobrevida e apoptose. Para além 
disso, estes recetores têm importãncia no controlo de secreção de fatores neutróficos 
e citoquinas, os quais também podem influenciar a função e expressão dos próprios 
recetores de adenosina. 
O envolvimento da microglia e a neuroinflamação são componentes 
importantes de doenças neurodegenerativas que também são objeto de controlo por 
parte da adenosina, assim como o impacto da infiltração de células imunes periféricas.
As propriedades pleiotrópicas do sistema da adenosina envolvem também um 
controlo da neuroinflamação crónica. Foi proposto que a adenosina, nomeadamente 
através dos recetores A2A produz um sinal “OFF” que coordena os diferentes estadios 
de inflamação e redireciona as respostas imunes após uma resposta proinflamatória 
inicial. No entanto, no sistema nervoso central esta ação não é clara e os resultados 
são controversos.  
A Adenosina em Patologias Neurológicas 
a) Doença de Alzheimer
A doença de Alzheimer (AD) é a forma mais comum de demência no idoso e é 
caracterizada por uma perda de memória e deterioração cognitiva progressivas. Em 
termos neuropatológicos, a AD resulta da deposição de placas de amiloide Aβ e 
formação de emaranhados neurofibrilares (NFT). Estas alterações estão associadas a 
morte neuronial, neuritos distróficos e disrupção sináptica assim como a processos 
neuroinflamatórios e de disfunção glial. Existem estudos que indicam uma diminuição 
da densidade dos recetores A1 em zonas importantes para o processamento cognitivo, 
embora se verifique um aumento e uma maior atividade deste recetor no córtex frontal, 
POTENTIAL OF ADENOSINE-SYSTEM-BASED THERAPIES IN THE TREATMENT OF NEUROIMMUNE DISORDERS
45
especialmente em neurites distróficas. A adenosina exerce, desta forma, influências 
positivas no processamento da proteína precursora de amiloide e na fosforilação tau, 
desacelerando a progressão da doença. Por outro lado, o bloqueio dos recetores A2A
previne quase completamente a neurotoxicidade e a perda sináptica induzida por Aβ. 
O mecanismo exato para esta proteção é desconhecido mas envolve provávelmente 
propriedades anti-inflamatórias, proteção contra radicais livres e o controlo de 
excitotoxicidade.
Outra linha de evidência do papel da adenosina na AD deriva dos benefícios 
cognitivos do consumo a longo prazo de cafeína observado em modelos animais e em 
estudos epidemiológicos. A cafeína é um antagonista não seletivo dos recetores A1 e 
A2A e manifesta uma tendência protetora e de reversão do declínio cognitivo. No 
entanto não é claro se o bloqueio A2A é o responsável por estes efeitos, ou se por
outro lado atuará mais especificamente em processos mais insidiosos de deterioração 
sináptica.
b) Doença de Parkinson
A doença de Parkinson (PD) é caracterizada por uma perda progressiva dos 
neurónios dopaminérgicos da substância negra pars compacta (SNc) de etiologia 
desconhecida, resultando em sintomas de acinésia, bradicinésia, rigidez, tremor em 
repouso e anomalias posturais. Na sua etiopatogenia está envolvida uma perda do 
controlo dopaminérgico das vias de inibição e facilitação do movimento.
Os recetores A2A estão envolvidos em vários aspetos da fisiopatologia da PD. A 
sua alta expressão no estriado e a formação de heterómeros com recetores de 
dopamina D2 (D2R) suscita a possibilidade da sua manipulação como terapia 
alternativa ou complementar às baseadas na dopamina. Com efeito, vários estudos 
epidemiológicos e experimentais em modelos animais confirmam um efeito de 
melhoria da atividade motora com o antagonismo dos recetores A2A, tanto em 
monoterapia como em conjunto com L-DOPA, mostrando um efeito sinérgico e uma 
redução dos efeitos laterais dos compostos dopaminomiméticos. No entanto, estudos 
clínicos contrastam com estas evidências e aguardam resultados mais sólidos para a 
aprovação destes fármacos.
Para além do benefício sintomático, o bloqueio A2A apresenta também um 
potencial modificador da doença, diminuindo a degeneração neuronial e impedindo a 
progressão, embora o mecanismo exato para esta proteção ainda estar por descobrir.
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c) Doença de Huntington
A doença de Huntington (HD) é caracterizada por uma coreia de agravamento 
progressivo, distúrbios psiquiátricos e défice cognitivo. É uma doença autossómica 
dominante em que ocorre degeneração dos neurónios medios espinhosos (MSNs) 
GABAergicos encefalinérgicos do estriado, que está relacionada com a forma mutada 
da proteina Hungtingtina. 
A observação de diferentes graus de expressão, densidade e sinalização dos 
recetores A2A consoante a fase da doença, aponta um alvo potencial na HD. A HD 
parece ser um caso especial em que ambos o bloqueio e a ativação do recetor  A2A
parecem apresentar propriedades neuroprotectoras. Tal poderá ser explicado através 
de um balanço entre a ação pré- versus pós-sináptica ou então pelos múltiplos 
mecanismos envolvidos na fisopatologia da HD em que o recetor A2A intervém. A título 
de exemplo, agonistas A2A têm a capacidade de transactivar o recetor trkB do BDNF 
(cuja produção e distribuíção é assegurada pela Hungtingtina normal) e atuam contra 
a formação de agregados de Hungtingtina, enquanto que o antagonismo A2A tem 
efeitos no controlo do componente neuroinflamatório da HD, inclusive na modulação 
de células inflamatórias periféricas infiltrantes.
d) Esclerose Múltipla
A eslerose múltipla (MS) é uma doença inflamatória desmielinizante e 
neurodegenerativa, definida por um dano autorreativo mediado por células T nos 
oligodendrócitos e na bainha de mielina dos axónios centrais.
Para além do papel da adenosina no controlo da comunicação neuroglial e glia-
glial, há muito pouca informação sobre a contribuição da sinalização purinérgica para a 
imunopatologia da MS. A adenosina, atuando nos recetores A1, protege contra a 
neuroinflamação, desmielinização e citotoxicidade. Além disso, este recetor apresenta 
níveis de expressão reduzidos em MS, sugerindo que a sua disfunção pode estar 
envolvida na patogénese da doença. Existem ainda evidências do papel do recetor A1
na transição de uma resposta imune Th1 para Th2, atenuando a patologia da MS.
Outro aspeto da fisiopatologia da MS controlado pela adenosina é a infiltração 
linfocitária no sistema nervoso central. Esta infiltração necessita da expressão de 
ectonucleotidases na superfície dos linfócitos. Por outro lado, se essa expressão 
estiver aumentada, pode também contribuir para o aumento da concentração de 
adenosina e para o controlo da inflamação. Existe, portanto uma controvérsia na 
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estratégia terapêutica a adotar, contrabalançando os efeitos anti-inflamatórios com a 
infiltração de células T patogénicas.    
Discussão
As perspetivas do futuro de terapias baseadas na adenosina em doenças 
neurodegenerativas crónicas é animadora. No entanto, apesar das descobertas nos 
últimos anos acerca da vasta contribuição dos recetores de adenosina para
mecanismos neuroprotetores e na regulação da inflamação, existem ainda várias 
questões em aberto que merecem especial atenção.
A adenosina desencadeia uma multiplicidade de efeitos em diferentes células, 
e fatores tais como a expressão, densidade, localização, sistema de transdução de 
sinal, e funções dos recetores da adenosina estão sujeitos a modificações consoante a 
atividade cerebral ou na presença de patologia. A mesma promiscuidade ocorre com a 
instituição de modulação farmacológica dos recetores ou das vias de metabolização 
da adenosina assim como após o consumo de cafeína, particularmente a longo-termo. 
Além disso, as fontes e as vias de geração de adenosina extracelular ainda não estão 
completamente caracterizadas de forma a compreender a dinâmica destes recetores.
Relativamente aos modelos experimentais de neurodegeneração, é difícil tecer 
conclusões sobre o papel específico dos recetores da adenosina em doenças 
crónicas, visto que grande parte das evidências é derivada de modelos de lesão aguda 
e por vezes não levam em conta a idade do animal. Isto tem particular relevância uma 
vez que doenças como AD e PD são altamente prevalentes no idoso.
Parece bem estabelecido que a ativação dos recetores A1 confere 
neuroprotecção enquanto que o bloqueio dos recetores A2A atenua a patologia na 
maioria das doenças cerebrais. Isto significaria que uma combinação de inibidores da 
adenosina cinase e antagonistas A2A resultaria no maior potencial neuroprotector. 
Contudo, este impacto só poderá ser previsto assim que seja clarificado como e 
quando é que se alteram os níveis cerebrais (incluindo sinapse e domínios neuro-glial, 
glia-glial e gliovascular) de adenosina extracelular. Além disso, tais flutuações podem 
variar consoante a doença e o seu estadio, o que complica este cenário.
O reconhecimento do papel duplo da neuroinflamação na neurodegeneração e 
neuroproteção, aliado à função de controlo do balanço entre dano e reparação 
tecidular do sistema adenosinérgico, levou à investigação das potencialidades da 
adenosina na modulação das funções gliais e imunes. O papel primordial aparente da 
adenosina de proteção fisiológica em danos agudos contrasta com a capacidade 
reduzida de proteção em condições crónicas. Os sinais mediados pela adenosina são 
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endogenamente protetores , mas imperfeitos e inconsistentes. Por exemplo, o 
bloqueio dos recetores A2A cerebrais para suprimir inflamação pode exacerbar efeitos 
proinflamatórios periféricos. Aliás, as interações com astrócitos e microglia têm 
provavelmente uma grande importância nesta modulação, visto que cada uma destas 
células gliais apresenta recetores de adenosina e têm efeitos opostos de promoção 
das respostas imunes e de inibição da inflamação do sistema nervoso central. 
No que concerne às doenças neurodegenerativas em específico, existem 
também alguns aspetos que merecem discussão.
Na AD ainda é difícil distinguir os impactos do bloqueio A2A no défice cognitivo 
daqueles que estão relacionados com a fisiopatologia da doença em si. Um alvo 
putativo a ser testado está relacionado com a função colinérgica. Foi observado que 
os recetores α-7 nicotínicos da acetilcolina estão aumentados no início da doença e 
que podem ser controlados pela ativação dos recetores A2A. Visto que há um défice de 
projeções colinérgicas em AD, o bloqueio de recetores A2A pode assim ter ainda mais 
um mecanismo de regulação de fenómenos de plasticidade neuronial.
Os últimos anos de investigação revolucionaram a visão clássica da PD. Na 
verdade, a neurodegeneração estende-se a outros locais e outros terminais e os 
circuitos de controlo motor dos gânglios da base são muito mais intrincados, 
dificultando a compreensão do papel da adenosina na sua fisiopatologia. Além disso, a 
caracterização e desenvolvimento de ligandos que tenham como alvo heterómeros 
que contenham o recetor A2A devem ser considerados no futuro. Estes têm 
propriedades farmacológicas únicas e são mais seletivos em localização do que cada 
um dos recetores constituintes, permitindo uma melhor perceção dos mecanismos 
envolvidos na doença.
As discrepâncias dos efeitos dos recetores A2A na HD têm sido o maior entrave 
no desenvolvimento de novas terapias. Agonistas A2A parecem apresentar maior
benefício em estadios tardios de degeneração enquanto que os efeitos protetores do 
bloqueio A2A dependem do grau de inibição pós-sináptica. Também aqui a formação 
de heterómeros que contenham o recetor A2A constitui um alvo mais específico e 
oportuno.
A investigação do papel específico do sistema adenosinérgico na fisiopatologia 
da MS está ainda no seu início. A MS pode ser vista como um modelo de 
autoimunidade protetora, em que os mecanismos naturais de reparação cerebral estão 
impedidos. Os recetores A1 parecem ser importantes na restauração desses 
mecanismos e a indução de aumentos de adenosina extracelular parece uma 
estratégia plausível.
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As múltiplas questões em aberto poderão obter resposta com a exploração das 
potencialidades dos recetores A2B e A3, assim como através do uso de novos 
agonistas e antagonistas, moduladores alostéricos e de heterómeros com diferentes 
afinidades e propriedades, criando nomeadamente um balanço adequado entre efeitos 
pré- e pós-sinápticos. A ação das ectonucleotidases também tem um papel importante 
na sinalização purinérgica de recetores de ATP versus adenosina, após se ter 
verificada a formação de complexos oligoméricos entre estes.
Também foi observado que a astrogliose reativa presente em muitas patologias 
cerebrais está associada a um aumento patológico da expressão de adenosina cinase. 
O uso lógico de inibidores desta enzima gerou, porém, efeitos laterais sistémicos 
significativos que incentivaram uma nova era de abordagens de aumento focal de 
adenosina. Aqui estão incluídas estratégias inteligentes como a distribuíção por 
polímeros, a distribuíção por células estaminais e a terapia génica.
Conclusões
Existe, portanto, um espectro inteiro de mecanismos fisio(pato)lógicos que 
estão sujeitos a regulação adenosinérgica. Terapias baseadas nesta abordagem irão 
depender do timing de tratamento, no que diz respeito à janela terapeutica, ao estadio 
e progressão dos danos e à duração e monitorização dos efeitos benéficos e 
adversos. Esta coincidência tempo-espaço será somente alcançada através de uma 
melhor compreensão sobre o modo como os sinais da adenosina são percebidos, 
discriminados, sustentados e terminados.  
